We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).
Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.
The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).
Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.
While the headlines often spotlight stocks that are soaring to new heights, some of the best investment prospects lie in stocks trading below their historical valuations
Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptance under Priority Review. The stock rises 16%.
Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.
Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.
pharmaceuticals: Archive
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
by Zacks Equity Research
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.
NVSPositive Net Change DVAXPositive Net Change ETONPositive Net Change
biotechnology pharmaceuticals
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
by Zacks Equity Research
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
NVSPositive Net Change MRKNegative Net Change SGENPositive Net Change ANVSNegative Net Change
biotechs medical pharmaceuticals vaccines
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.
AZNPositive Net Change NVSPositive Net Change LLYPositive Net Change ANVSNegative Net Change
biotechs medical pharmaceuticals
AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study
by Zacks Equity Research
AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.
AZNPositive Net Change DVAXPositive Net Change GILDNegative Net Change CORTPositive Net Change
biotechs immuno-therapy medical pharmaceuticals
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
DVAXPositive Net Change MRKNegative Net Change SGENPositive Net Change CORTPositive Net Change
biotechnology biotechs cell-therapy immuno-therapy medical pharmaceuticals
The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca
by Zacks Equity Research
Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.
AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change
large-cap pharmaceuticals
Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
BRPositive Net Change PAYXPositive Net Change NVONegative Net Change PGNegative Net Change AMGNNegative Net Change MSCIPositive Net Change SMSEYNegative Net Change BCCPositive Net Change SABRPositive Net Change NOBLPositive Net Change ELMTYNo Net Change CELHPositive Net Change
consumer-staples fin-tech pharmaceuticals
Top Stock Reports for Amazon.com, Boeing, Regeneron & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).
BAPositive Net Change AMZNPositive Net Change REGNPositive Net Change BSXPositive Net Change MONegative Net Change WMPositive Net Change
aerospace biotechnology pharmaceuticals retail
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
by Zacks Equity Research
Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.
NVSPositive Net Change ANVSNegative Net Change CALTPositive Net Change TVTXPositive Net Change
biotechs medical pharmaceuticals
Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications
by Kinjel Shah
The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.
AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health
by Zacks Equity Research
Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.
ACNPositive Net Change TMNegative Net Change LLYPositive Net Change CVSPositive Net Change DISNegative Net Change
auto-tires-trucks business-services consumer-discretionary medical pharmaceuticals
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
by Zacks Equity Research
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
DVAXPositive Net Change CORTPositive Net Change MBRXPositive Net Change BTTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway
by Zacks Equity Research
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
DVAXPositive Net Change CORTPositive Net Change AQSTNegative Net Change BTTXPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Top Research Reports for Eli Lilly, Toyota Motor, Accenture & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).
ACNPositive Net Change TMNegative Net Change PLDNegative Net Change LLYPositive Net Change CVSPositive Net Change DISNegative Net Change
auto-tires-trucks business-services pharmaceuticals
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
by Zacks Equity Research
Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.
DVAXPositive Net Change CORTPositive Net Change ATRANegative Net Change BTTXPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
NVSPositive Net Change MRKNegative Net Change CORTPositive Net Change AUPHNegative Net Change
pharmaceuticals
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
by Zacks Equity Research
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
NVSPositive Net Change MRKNegative Net Change APRENegative Net Change ANVSNegative Net Change
biotechs medical pharmaceuticals
Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
by Zacks Equity Research
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
DVAXPositive Net Change GILDNegative Net Change CORTPositive Net Change BTTXPositive Net Change
biotechs medical pharmaceuticals
Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View
by Zacks Equity Research
Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.
MRKNegative Net Change JAZZPositive Net Change LGNDNegative Net Change
biotechs medical pharmaceuticals vaccines
Discount Alert: 3 Top Ranked Stocks Trading Below Historical Valuations
by Ethan Feller
While the headlines often spotlight stocks that are soaring to new heights, some of the best investment prospects lie in stocks trading below their historical valuations
RDYNegative Net Change CATPositive Net Change OCPositive Net Change
construction pharmaceuticals
Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up
by Zacks Equity Research
Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptance under Priority Review. The stock rises 16%.
DVAXPositive Net Change CORTPositive Net Change ORTXPositive Net Change BTTXPositive Net Change
biotechs medical pharmaceuticals
Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod
by Zacks Equity Research
Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.
DVAXPositive Net Change PFEPositive Net Change LLYPositive Net Change CORTPositive Net Change
biotechs medical pharmaceuticals
Here's Why You Should Invest in Alpine (ALPN) Stock Now
by Zacks Equity Research
Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
CORTPositive Net Change AUPHNegative Net Change KALVPositive Net Change ALPNPositive Net Change
pharmaceuticals
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
by Zacks Equity Research
Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.
CORTPositive Net Change AUPHNegative Net Change KALVPositive Net Change ALPNPositive Net Change CRDLNegative Net Change
medical pharmaceuticals
Novartis' (NVS) Shareholders Approve Sandoz Separation
by Zacks Equity Research
Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.
NVSPositive Net Change DVAXPositive Net Change ETONPositive Net Change BLCOPositive Net Change
pharmaceuticals